Cardiovascular, Renal & Metabolic Disease

Cardiovascular, renal and metabolic (CVRM) diseases – including obesity and associated comorbidities such as diabetes, chronic kidney disease, heart and liver diseases – are deeply interconnected and place a growing burden on individuals, healthcare systems and societies. They affect a substantial share of adults globally and cause millions of deaths annually:

• Nearly three in ten adults are estimated to have metabolic syndrome1

• About 43% of adults are living with overweight2

• One in nine adults lives with diabetes,3 and

• One in three adults aged 30–79 has hypertension.4

Despite the availability of numerous treatment options, significant gaps remain in addressing the unmet needs of patients, as many therapies have not significantly altered disease trajectories. Advances in human genetics and disease biology have identified new therapeutic targets, and innovative modalities such as siRNAs, ASOs, cell therapies, and gene silencing which are opening doors to treatments for previously untreatable conditions.

Roche is uniquely positioned to address these challenges with its comprehensive pipeline of potential best- and first-in-class investigational medicines, Diagnostics and Digital Solutions aimed at improving outcomes, reducing societal burdens, and transforming care for patients with CVRM diseases throughout their journey. We are highly committed to contributing to areas of highest unmet need and societal burden through transformative science, expanding our footprint in cardiovascular and metabolic diseases.

• Uncontrolled hypertension

• Obesity  (also in context of Diabetes)

• MASH (metabolic dysfunction-associated steatohepatitis)

• Myocardial infarction/ stroke secondary prevention

• Cardiomyopathies

• SPAF (stroke & systemic embolic prevention in atrial fibrillation)